Medications for Retinal Vein Occlusion
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Retinal Vein Occlusion.
Found 3 Approved Drugs for Retinal Vein Occlusion
Ranibizumab
Brand Names
Lucentis, Byooviz, Susvimo, Cimerli
Ranibizumab
Brand Names
Lucentis, Byooviz, Susvimo, Cimerli
Form: Injection
Method of administration: Intravitreal
FDA approval date: June 30, 2006
Classification: Vascular Endothelial Growth Factor Inhibitor
CIMERLI is indicated for the treatment of patients with: CIMERLI, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD).
Aflibercept
Brand Names
Eylea, Zaltrap, Pavblu
Aflibercept
Brand Names
Eylea, Zaltrap, Pavblu
Form: Injection, Solution
Method of administration: Intravitreal, Intravenous
FDA approval date: November 21, 2011
Classification: Vascular Endothelial Growth Factor Inhibitor
EYLEA HD is indicated for the treatment of: EYLEA HD is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
Vabysmo
Generic Name
Faricimab
Vabysmo
Generic Name
Faricimab
Form: Injection
Method of administration: Intravitreal
FDA approval date: January 28, 2022
VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with: VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD).
Showing 1-3 of 3
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances